Skip to main content
Home
Logo SphingotecLogo Sphingotec

Biomarker out-licensing  

Accelerating market adoption through strategic partnerships

At SphingoTec, we believe that the broad adoption of innovative diagnostics is best achieved through collaboration. To make our first-in-class biomarkers available to clinicians and patients worldwide, we partner with leading global IVD companies. Our portfolio is available for licensing to organizations seeking to enrich their immunoassay offerings and to develop biomarker-based diagnostics for clinical use on high-throughput and near-patient testing platforms.

Licensing enables partners to:

  • Integrate SphingoTec’s biomarkers into their diagnostic platforms for laboratory or near-patient testing.
  • Accelerate time-to-market with robust, ready-to-implement biomarkers supported by strong scientific and clinical evidence.
  • Benefit from SphingoTec’s development expertise and established clinical networks.

Ready-to-scale solutions

We have developed a robust blueprint-shaped by strategic accomplishments-to minimize development uncertainties and accelerate market readiness for innovative biomarkers on third-party platforms.

1. Robust scientific foundation

We have established a proven link between disease pathways and our biomarkers, backed by extensive scientific evidence and high analytical accuracy of the reference technologies.

2. Intellectual property security

Our innovations are protected by strong patents, ensuring a competitive advantage in the market.

3. Proven clinical utility

Our biomarkers are scientifically validated and address unmet clinical needs, with proven utility demonstrated by successful proof-of-concept in leading hospitals and routine clinical use.

4. Market-ready solution

Our assays are developed for clinical relevance and scalability, offering a robust blueprint for seamless integration into partner diagnostic pipelines—ideal for in-licensing by companies seeking innovative biomarker solutions.

5. Multidisciplinary expertise

Our team possesses deep expertise in critical care biomarkers, assay development, clinical implementation, and collaborations with leading academic and medical centers.

Bio-ADM: endothelial function biomarker

Bio-ADM is a dynamic biomarker for the real-time assessment of endothelial function. Loss of endothelial function is causing the formation of edema, shock and subsequent organ failure in critically ill patients.

Discover more

Three dimensional illustration of blood vessel with flowing erythrocytes and leukocytes.
Human kidney cross section on blue, science background.

PenKid: kidney function biomarker

PenKid is a dynamic biomarker for the real time assessment of kidney function. PenKid is a blood-based alternative to standard biomarkers that correlates with the true glomerular filtration rate (true GFR).

Discover more

Contact us

Do you have any questions or require more information?
We are looking forward to talking to you!

email: info[at]sphingotec.com

Deborah Bergmann

Managing Director & CEO

*Disclaimer

Sphingotest® penKid®, and sphingotest® bio-ADM® are offered for research use only. “penKid” and “bio-ADM” represent the analytes Proenkephalin A 119-159 and bioactive Adrenomedullin 1-52, respectively.